Cargando…

South African healthcare workers’ knowledge of dolutegravir's drug–drug interactions in the first year of its rollout: a cross‐sectional online survey

INTRODUCTION: In December 2019, dolutegravir‐based treatment was recommended as first‐line antiretroviral therapy (ART) in South Africa. Dolutegravir has clinically significant interactions with several commonly used drugs, such as rifampicin, metformin and cation‐containing medicines. National guid...

Descripción completa

Detalles Bibliográficos
Autores principales: Chisholm, Briony S., Swart, Annoesjka M., Blockman, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901146/
https://www.ncbi.nlm.nih.gov/pubmed/35255196
http://dx.doi.org/10.1002/jia2.25885
_version_ 1784664294245269504
author Chisholm, Briony S.
Swart, Annoesjka M.
Blockman, Marc
author_facet Chisholm, Briony S.
Swart, Annoesjka M.
Blockman, Marc
author_sort Chisholm, Briony S.
collection PubMed
description INTRODUCTION: In December 2019, dolutegravir‐based treatment was recommended as first‐line antiretroviral therapy (ART) in South Africa. Dolutegravir has clinically significant interactions with several commonly used drugs, such as rifampicin, metformin and cation‐containing medicines. National guidelines detail these interactions and how to manage them. While previous international studies have shown low healthcare worker knowledge of drug–drug interactions, there is a paucity of information on antiretroviral interaction knowledge in the South African setting, where much ART is nurse‐led. The study aimed to determine this knowledge and to describe which variables were associated with gaps in knowledge. METHODS: An anonymous online survey of healthcare workers in the field of HIV was conducted in August/September 2020. The survey was designed, tested and piloted, and included sections on demographics, guideline access and training, interaction knowledge, counselling and the effect of COVID‐19. Dissemination was via e‐mail and social media (convenience sampling). Descriptive and inferential analysis was done using proportions and the 95% confidence interval to determine relationships between independent and dependent variables. Research ethics approval was obtained from the University of Cape Town's Human Research Ethics Committee (HREC Ref: 357/2020). RESULTS AND DISCUSSION: In total, 1950 survey responses were included in the analysis – 47.1% nurses, 35.8% doctors and 8.9% pharmacists. When asked whether they were aware that dolutegravir has interactions, 70% said yes, 13.9% said no and 16.1% did not answer. Knowledge of specific interactions and the dosing changes needed was low with a wide range between different drugs: 79.7% knew to double the dolutegravir dose with rifampicin, but with calcium, 5.1% picked both correct dosing options and 33.7% picked one of the two correct options. Access to guidelines and training were positively associated with drug interaction knowledge. CONCLUSIONS: There are gaps in the awareness and knowledge of dolutegravir interactions and how to adjust dosing among South African healthcare workers.
format Online
Article
Text
id pubmed-8901146
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-89011462022-03-11 South African healthcare workers’ knowledge of dolutegravir's drug–drug interactions in the first year of its rollout: a cross‐sectional online survey Chisholm, Briony S. Swart, Annoesjka M. Blockman, Marc J Int AIDS Soc Short Report INTRODUCTION: In December 2019, dolutegravir‐based treatment was recommended as first‐line antiretroviral therapy (ART) in South Africa. Dolutegravir has clinically significant interactions with several commonly used drugs, such as rifampicin, metformin and cation‐containing medicines. National guidelines detail these interactions and how to manage them. While previous international studies have shown low healthcare worker knowledge of drug–drug interactions, there is a paucity of information on antiretroviral interaction knowledge in the South African setting, where much ART is nurse‐led. The study aimed to determine this knowledge and to describe which variables were associated with gaps in knowledge. METHODS: An anonymous online survey of healthcare workers in the field of HIV was conducted in August/September 2020. The survey was designed, tested and piloted, and included sections on demographics, guideline access and training, interaction knowledge, counselling and the effect of COVID‐19. Dissemination was via e‐mail and social media (convenience sampling). Descriptive and inferential analysis was done using proportions and the 95% confidence interval to determine relationships between independent and dependent variables. Research ethics approval was obtained from the University of Cape Town's Human Research Ethics Committee (HREC Ref: 357/2020). RESULTS AND DISCUSSION: In total, 1950 survey responses were included in the analysis – 47.1% nurses, 35.8% doctors and 8.9% pharmacists. When asked whether they were aware that dolutegravir has interactions, 70% said yes, 13.9% said no and 16.1% did not answer. Knowledge of specific interactions and the dosing changes needed was low with a wide range between different drugs: 79.7% knew to double the dolutegravir dose with rifampicin, but with calcium, 5.1% picked both correct dosing options and 33.7% picked one of the two correct options. Access to guidelines and training were positively associated with drug interaction knowledge. CONCLUSIONS: There are gaps in the awareness and knowledge of dolutegravir interactions and how to adjust dosing among South African healthcare workers. John Wiley and Sons Inc. 2022-03-07 /pmc/articles/PMC8901146/ /pubmed/35255196 http://dx.doi.org/10.1002/jia2.25885 Text en © 2022 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Report
Chisholm, Briony S.
Swart, Annoesjka M.
Blockman, Marc
South African healthcare workers’ knowledge of dolutegravir's drug–drug interactions in the first year of its rollout: a cross‐sectional online survey
title South African healthcare workers’ knowledge of dolutegravir's drug–drug interactions in the first year of its rollout: a cross‐sectional online survey
title_full South African healthcare workers’ knowledge of dolutegravir's drug–drug interactions in the first year of its rollout: a cross‐sectional online survey
title_fullStr South African healthcare workers’ knowledge of dolutegravir's drug–drug interactions in the first year of its rollout: a cross‐sectional online survey
title_full_unstemmed South African healthcare workers’ knowledge of dolutegravir's drug–drug interactions in the first year of its rollout: a cross‐sectional online survey
title_short South African healthcare workers’ knowledge of dolutegravir's drug–drug interactions in the first year of its rollout: a cross‐sectional online survey
title_sort south african healthcare workers’ knowledge of dolutegravir's drug–drug interactions in the first year of its rollout: a cross‐sectional online survey
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901146/
https://www.ncbi.nlm.nih.gov/pubmed/35255196
http://dx.doi.org/10.1002/jia2.25885
work_keys_str_mv AT chisholmbrionys southafricanhealthcareworkersknowledgeofdolutegravirsdrugdruginteractionsinthefirstyearofitsrolloutacrosssectionalonlinesurvey
AT swartannoesjkam southafricanhealthcareworkersknowledgeofdolutegravirsdrugdruginteractionsinthefirstyearofitsrolloutacrosssectionalonlinesurvey
AT blockmanmarc southafricanhealthcareworkersknowledgeofdolutegravirsdrugdruginteractionsinthefirstyearofitsrolloutacrosssectionalonlinesurvey